Showing papers in "Blood in 2007"

TL;DR: The aim of this review is to critically discuss the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms, the potential clinical use of M SCs as modulators of immune responses in vivo and to indicate clinical safety concerns and recommendations for future research.

TL;DR: It is established that CFU-ECs are not EPCs and the role of these cells in angiogenesis must be re-examined prior to further clinical trials, whereas ECFCs may serve as a potential therapy for vascular regeneration.

TL;DR: The findings suggest that targeting this metabolic pathway in tumors is a promising strategy to enhance tumor immunogenicity and block lactic acid export in T cells, thereby disturbing their metabolism and function.

TL;DR: A retrospective analysis of patients with DLBCL treated with R-CHOP to assess the value of the IPI in the era of immunochemotherapy found it to be a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials.

TL;DR: These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides and Sézary syndrome to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS.

TL;DR: In humans CD39 is a marker of a Treg subset likely involved in the control of the inflammatory autoimmune disease and Notably, patients with the remitting/relapsing form of multiple sclerosis have strikingly reduced numbers of CD39(+) Treg cells in the blood.

TL;DR: In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as predictive of survival as donor HLA matching, and high-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival.

TL;DR: Vorinostat demonstrated activity in heavily pretreated patients with CTCL and the 400 mg daily regimen had the most favorable safety profile and is being further evaluated.

TL;DR: Protein expression and functional studies showed that PI3K and eNOS play a critical role in the angiogenic effect of MVs, suggesting that EPCs may activate angiogenesis in endothelial cells by releasing MVs able to trigger an angiogens program.

TL;DR: It is found that Stat5 phosphorylation in T cells is suppressed in the presence of MSCs and that nitric oxide (NO) is involved in the suppression of Stat5osphorylation and T-cell proliferation, and that NO produced by Mscs is one of the major mediators of T- cell suppression by M SCs.

TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.

TL;DR: In this paper, the authors proposed a revision of the current World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which was subsequently presented by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders.

TL;DR: It is shown that an early HSC population that might reside in the low-oxygenic niche can be functionally isolated by taking advantage of the relative intracellular ROS activity and treatment with an antioxidant, a p38 inhibitor, or rapamycin was able to restore HSC function in the ROS(high) population.

TL;DR: Experiments demonstrated that T cells from GCN2 knock-out mice did not show a decreased proliferation and were able to up-regulate cyclin D3 when cultured in the absence of L-Arg, contributing to the understanding of a central mechanism by which cancer and other diseases characterized by high arginase I production may cause T-cell dysfunction.

TL;DR: Nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance and was effective in patients harboring BCR-ABL mutations associated with imatinIB resistance (except T315I), and also in Patients with a resistance mechanism independent of B CR-ABl mutations.

TL;DR: A large, unique database that includes morphologic, clinical, cytogenetic, and follow-up data from 2124 patients with myelodysplastic syndromes (MDSs) offers new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS.

TL;DR: This review summarizes insights gleaned from recent in vitro and in vivo studies of the direct cytoprotective effects of APC that include beneficial alterations in gene expression profiles, anti-inflammatory actions, antiapoptotic activities, and stabilization of endothelial barriers that suggest the possibility of developing APC variants with an improved profile for the ratio of cy toprotective to anticoagulant actions.

TL;DR: It is concluded from a large, unselected series with mature follow-up that most adults with recurring ALL cannot be rescued using currently available therapies and prevention of recurrence is the best strategy for long-term survival in this disease.

TL;DR: This paper showed that TCR stimulation alone was insufficient to induce FOXP3 expression in the absence of transforming growth factor β (TGFβ), whereas high levels of expression could be induced in the presence of TGFβ.

TL;DR: It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.

TL;DR: Risks of several CVDs are 3- to 5-fold increased in survivors of HL compared with the general population, even after prolonged follow-up, leading to increasing absolute excess risks over time.

TL;DR: It is demonstrated that the gene encoding oncogenic microRNA-21 (miR-21) is controlled by an upstream enhancer containing 2 Stat3 binding sites strictly conserved since the first observed evolutionary appearance of miR- 21 and Stat3.

TL;DR: The term Trousseau's syndrome is extended to include chronic disseminated intravascular coagulopathy associated with microangiopathy, verrucous endocarditis, and arterial emboli in patients with cancer, often occurring with mucin-positive carcinomas.

TL;DR: The identification of shear-dependent mechanisms of platelet aggregation has raised the possibility that vascular-bed-specific inhibitors of platelets aggregation may be developed in the future that are safer and more effective than existing antiplatelet agents.

TL;DR: Two second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed and comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs were generated to predict potential side effects and novel medical uses.

TL;DR: The results suggest that BMP9 and BMP10 are two specific ALK1 ligands that may physiologically trigger the effects ofALK1 on angiogenesis.

TL;DR: It is concluded that the developmental fate of BM-derived cells is not restricted by the surrounding tissue after myocardial infarction and that the MSC fraction underlies the extended bone formation in the infarcted myocardium.

TL;DR: An observational study to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied.

TL;DR: Dasatinib induces notable responses in imatinib-resistant or -intolerant CML-CP, is well tolerated, and represents a promising therapeutic option for these patients.

TL;DR: Monitoring of imatinib plasma levels could be very useful for the management of patients with CML or should at least be checked in the case of treatment failure or suboptimal response.